Irlanda - engleză - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd t/a gerard laboratories - irbesartan - tablets - 75 milligram

Irlanda - engleză - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd t/a gerard laboratories - irbesartan - tablets - 150 milligram

Irlanda - engleză - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd t/a gerard laboratories - irbesartan - tablets - 300 milligram

Canada - engleză - Health Canada

mylan pharmaceuticals ulc - clopidogrel (clopidogrel bisulfate) - tablet - 300mg - clopidogrel (clopidogrel bisulfate) 300mg - platelet aggregation inhibitors

Irlanda - engleză - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd t/a gerard laboratories - irbesartan - tablets - 75 milligram

Irlanda - engleză - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd t/a gerard laboratories - irbesartan - tablets - 150 milligram

Irlanda - engleză - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd t/a gerard laboratories - irbesartan - tablets - 300 milligram

Australia - engleză - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - hydrochlorothiazide,irbesartan -

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

west-ward pharmaceuticals corp. - irbesartan (unii: j0e2756z7n) (irbesartan - unii:j0e2756z7n), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - irbesartan 150 mg - irbesartan and hydrochlorothiazide is indicated for the treatment of hypertension. irbesartan and hydrochlorothiazide may be used in patients whose blood pressure is not adequately controlled on monotherapy. irbesartan and hydrochlorothiazide may also be used as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals. the choice of irbesartan and hydrochlorothiazide as initial therapy for hypertension should be based on an assessment of potential benefits and risks. patients with stage 2 (moderate or severe) hypertension are at relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. the decision to use a combination as initial therapy should be individualized and may be shaped by considerations such as the baseline blood pressure, the target goal, and the incremental likelihood of achieving goal with a combination compared with monotherapy

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

hisun pharmaceuticals usa inc. - irbesartan (unii: j0e2756z7n) (irbesartan - unii:j0e2756z7n), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - irbesartan 150 mg - irbesartan and hydrochlorothiazide tablets usp are indicated for the treatment of hypertension. irbesartan and hydrochlorothiazide tablets usp may be used in patients whose blood pressure is not adequately controlled on monotherapy. irbesartan and hydrochlorothiazide tablets usp may also be used as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals. the choice of irbesartan and hydrochlorothiazide tablets usp as initial therapy for hypertension should be based on an assessment of potential benefits and risks. patients with stage 2 (moderate or severe) hypertension are at relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. the decision to use a combination as initial therapy should be individualized and may be shaped by considerations such as the baseline blood pressure, the target goal, and the incremental likelihood of achieving